medigraphic.com
ISSN 1025-0298 (Electronic)
ISSN 1025-028X (Print)

2016, Number 2

Next >>

VacciMonitor 2016; 25 (2)

Development of a PCR assay to detect cholera toxin genes (ctxAB) in preparations of attenuated live vaccine candidate against cholera CV638

Peidro-Guzmán H, Marrero-Domínguez K, Ledón-Pérez T, Fando-Calzada R

Language: Spanish
References: 21
Page: 30-36
PDF size: 106.66 Kb.


ABSTRACT

The live oral vaccine candidate against cholera CV638 is produced under Good Manufacturing Practices. The active ingredient of this vaccine candidate is the genetically modifi ed strain Vibrio cholerae 638; developed by researchers at the National Center of Scientifi c Research, from the strain V. cholerae serogroup O1 biotype El Tor C7258 (Peru, 1991), by removing cholera toxin genes (ctxAB). Since the strain 638 lacks these genes in its genome, the presence of ctxAB in vaccine preparations would be given by a contamination with a toxigenic V. cholerae strain. The present study aimed at designing a specific PCR to detect ctxAB genes in DNA isolated from preparations of the vaccine candidate CV638, artifi cially contaminated with toxigenic V. cholerae strain. Sensitivity of the optimized PCR assay was 1 pg of genomic DNA from toxigenic strain of V. cholerae C7258, corresponding to ~200 genomic copies. The sensitivity of the PCR method for detecting toxigenic strains in CV638 vaccine preparations contaminated with a toxigenic strain was ~7 x 103 colony forming units of the toxigenic strain per dose of CV638. Once validated, this method could be used in the quality control of the production of the live vaccine candidate CV638.


REFERENCES

  1. Harris JB, La Rocque RC, Qadri F, Ryan ET, Calderwood SB. Cholera. Lancet 2012;379(9835):2466-76.

  2. O’Ryan M, Vidal R, Del Canto F, Carlos SJ, Montero D. Vaccines for viral and bacterial pathogens causing acute gastroenteritis: Part I: Overview, vaccines for enteric viruses and Vibrio cholerae. Hum Vaccin Immunother 2015;11(3):584- 600.

  3. Pastor M, Pedraz JL, Esquisabel A. The state-of-the-art of approved and under-development cholera vaccines. Vaccine 2013;31(38):4069-78.

  4. Benítez JA, García L, Silva A, García H, Fando R, Cedré B, et al. Preliminary assessment of the safety and immunogenicity of a new CTXPhi-negative, hemagglutinin/protease-defective El Tor strain as a cholera vaccine candidate. Infect Immun 1999;67(2):539-45.

  5. Centro para el control estatal de la calidad de los medicamentos (CECMED). Validación de métodos analíticos. Regulación No. 41-2007. La Habana: CECMED; 2007.

  6. Dalusi L, Lyimo TJ, Lugomela C, Hosea KM, Sjoling S. Toxigenic Vibrio cholerae identifi ed in estuaries of Tanzania using PCR techniques. FEMS Microbiol Lett 2015;362(5): doi:10.1093/femsle/fnv009.

  7. Studer E, Candrian U. Development and validation of a detection system for wild-type Vibrio cholerae in genetically modifi ed cholera vaccine. Biologicals 2000;28(3):149-54.

  8. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: A Laboratory Manual. 2nd ed. New York: Cold Spring Harbor; 1989.

  9. Heidelberg JF, Eisen JA, Nelson WC, Clayton RA, Gwinn ML, Dudson RJ, et al. DNA sequence of both chromosomes of the cholera pathogen Vibrio cholerae. Nature 2000;406(6795):477- 83.

  10. Ausubel FM, Brent R, Kingston RE, Moore DD; Seidman JG, Smith JA, et al, editors. Short protocols in molecular biology. 3rd ed. New York: John Wiley & Sons; 1995.

  11. WHO. Cholera, 2013. Wkly Epidemiol Rec 2014;89(31):345- 56.

  12. Li F, Kan B, Wang D. Development of both multiple PCR and real-time SYBR green PCR for the detection of Vibrio cholerae non-O1/O139 serogroups. Zhonghua Liu Xing Bing Xue Za Zhi. 2014;35(1):66-70.

  13. Vinothkumar K, Bhardwaj AK, Ramamurthy T, Niyogi SK. Triplex PCR assay for the rapid identifi cation of 3 major Vibrio species, Vibrio cholerae, Vibrio parahaemolyticus, and Vibrio fl uvialis. Diagn Microbiol Infect Dis 2013;76(4):526-8.

  14. Wei S, Zhao H, Xian Y, Hussain MA, Wu X. Multiplex PCR assays for the detection of Vibrio alginolyticus, Vibrio parahaemolyticus, Vibrio vulnifi cus, and Vibrio cholerae with an internal amplifi cation control. Diagn Microbiol Infect Dis 2014;79(2):115-8.

  15. Chuang LY, Cheng YH, Yang CH. Specifi c primer design for the polymerase chain reaction. Biotechnol Lett 2013;35(10):1541-9.

  16. Ye J, Coulouris G, Zaretskaya I, Cutcutache I, Rozen S, Madden TL. Primer-BLAST: a tool to design target-specifi c primers for polymerase chain reaction. BMC Bioinformatics 2012;(13): doi:10.1186/1471-2105-13-134.

  17. Apte A, Daniel S. PCR primer design. Cold Spring Harb Protoc. 2009;(3): doi:10.1101/pdb.ip65.

  18. Dieffenbach CW, Lowe TM, Dveksler GS. General concepts for PCR primer design. PCR Methods Appl 1993;3(3):S30-S37

  19. Kumar A, Chordia N. In silico PCR primer designing and validation. Methods Mol Biol 2015;1275:143-51.

  20. Gardes J, Croce O, Christen R. In silico analyses of primers used to detect the pathogenicity genes of Vibrio cholerae. Microbes Environments. 2012;27(3):250–6.

  21. Safa A, Nair GB, Kong RY. Evolution of new variants of Vibrio cholerae O1. Trends Microbiol 2010;18(1):46-54.




2020     |     www.medigraphic.com